Merck & Company Inc (MRK)vsPhathom Pharmaceuticals Inc (PHAT)
MRK
Merck & Company Inc
$146.72
-0.14%
HEALTHCARE · Cap: $368.89B
PHAT
Phathom Pharmaceuticals Inc
$5.25
+3.35%
HEALTHCARE · Cap: $466.61M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 24412% more annual revenue ($67.38B vs $274.88M). MRK leads profitability with a 3.6% profit margin vs -30.2%. MRK earns a higher WallStSmart Score of 44/100 (D).
MRK
Hold44
out of 100
Grade: D
PHAT
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-76.6%
Fair Value
$84.66
Current Price
$146.72
$62.06 premium
Intrinsic value data unavailable for PHAT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 4.5B in free cash flow
Revenue surging 71.1% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.6x book value
4.7% revenue growth
ROE of 7.6% — below average capital efficiency
3.6% margin — thin
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -3489.0% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : PHAT
The strongest argument for PHAT centers on Revenue Growth, Debt/Equity. Revenue growth of 71.1% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Bear Case : PHAT
The primary concerns for PHAT are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while PHAT is a hypergrowth play — different risk/reward profiles.
PHAT carries more volatility with a beta of 0.50 — expect wider price swings.
PHAT is growing revenue faster at 71.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (44/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Phathom Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?